This concept was further validated when TILT-517-infected ovarian cancer samples showed significantly higher levels of chemoattractant (e.g., C-X-C motif chemokine ligand 10 (CXCL10)) compared to controls, leading to a substantial increase in ex vivo recruitment of cytotoxic CD4+ and CD8+ T cells in TILT-517-treated samples [27] (Fig. 2; Table 1). This evidence concerns the gene CXCL10 and ovarian carcinoma.